Has Dustin Deming, MD received payments from drug or device companies?

Yes. Drug and device makers reported $99,985 in general payments to Dustin Deming, MD across 86 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Dustin Deming, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Dustin Deming, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Dustin Deming, MD

Medical Oncology · Madison, WINPI 1831393883

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (59.5%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 21.6%. 2025 is the largest year on record at $28,073, 3.3 times the $8,430 reported in 2019. Among medical oncology clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$99,985in general payments, 2019–2025

Across 86 payments — averaging $1162.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Array Biopharma Inc$22K
E.r. Squibb & Sons, L.L.C.$19K
Pfizer$10K
Regeneron$9K
Bayer$8K
Taiho Oncology, Inc.$8K
plus $24K from 11 others

$8,004,399in research payments, 2019–2025

Across 169 payments — averaging $47,363 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Ipsen Biopharmaceuticals, Inc$2.6M
Merck$1.7M
Eli Lilly$1M
E.r. Squibb & Sons, L.L.C.$1M
Aadi Bioscience, Inc.$783K
Pfizer$501K
plus $395K from 7 others

What the payments were for

Consulting fees$59,47559%
Speaking & faculty fees$33,25833%
Travel & lodging$4,1964%
Food & beverage$3,0063%
Education$510%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Array Biopharma Inc	13	$21,572
E.r. Squibb & Sons, L.L.C.	19	$19,236
Pfizer	10	$10,110
Regeneron	7	$8,869
Bayer	4	$8,000
Taiho Oncology, Inc.	7	$7,833
Lilly USA, LLC	1	$4,900
Seagen Inc.	2	$4,239
Novocure Inc.	6	$3,395
Exelixis Inc.	2	$3,300
GSK	2	$2,800
Illumina, Inc.	1	$2,226
Aurobindo Pharma USA, Inc.	1	$1,500
Foundation Medicine, Inc.	2	$1,298
Genentech USA, Inc.	3	$360
Ipsen Biopharmaceuticals, Inc	5	$298
Promega Corporation	1	$51

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$99,985 in reported general payments places this provider in the 95th percentile of 54 medical oncology providers in Wisconsin.

See all medical oncology providers in Wisconsin →

Medicare billing

Part B allowed, 2024

$28,218

Medicare patients

117

Services billed

470

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Dexamethasone	47	$601
Ondansetron Hcl	47	$297
Pantoprazole Sodium	11	$184
Prochlorperazine Maleate	21	$160
Gabapentin	13	$153

Paid to pharmacies, not to this prescriber.

Other medical oncology in Madison

Joshua LangMadison$114K
Kari WisinskiMadison$43K
Justine BruceMadison$25K
Glenn LiuMadison$13K
Toby CampbellMadison$12K
Douglas McNeelMadison$7K
Noelle LoconteMadison$4K
Anthony SerritellaMadison$2K
Howard BaileyMadison$553
George WildingMadison$383

See the full list for Wisconsin →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →